Endologix Announces Release Date for Third Quarter 2016 Financial Results and Details of 2016 Investor Meeting
October 24 2016 - 9:00AM
Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative
treatments for aortic disorders, announced today details relating
to the release of its third quarter 2016 financial results, which
will take place on Tuesday, November 1, 2016 after the close of the
market, and its 2016 Investor Meeting, which will take place
November 17, 2016 at the Sheraton New York Times Square Hotel in
New York City.
Third Quarter 2016 Conference Call
Information Endologix will hold a conference call on
Tuesday, November 1, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss
the financial results of the third quarter 2016. The dial-in
numbers are (877) 407-0789 for domestic callers and (201) 689-8562
for international callers. A live webcast of the conference call
will be available online from the investor relations page of the
Company's corporate website at www.endologix.com.
After the live webcast, a replay of the webcast
will remain available online from the investor relations page of
Endologix's website, www.endologix.com, through November 1, 2017.
In addition, a transcript will be posted to website and a
telephonic replay of the call will be available until November 8,
2016. The replay dial-in numbers are (844) 512-2921 for domestic
callers and (412) 317-6671 for international callers. Please
use the replay pin number 13648565.
2016 Investor MeetingEndologix
will hold its 2016 Investor Meeting on November 17,
2016 from 4:30 to 7:00 pm ET at the Sheraton New
York Times Square Hotel in New York City. The event will include a
Company update along with presentations from prominent physicians
on the Company’s product portfolio and a question and answer
session with the physicians and Endologix management.
Event: |
|
Endologix Investor Meeting |
Date: |
|
November
17, 2016 |
Time: |
|
4:30 to
7:00 pm ET (registration and refreshments begin at 4:30
pm ET; formal presentation begins at 5:00 pm ET) |
Location: |
|
Sheraton
New York Times Square Hotel |
|
|
811 7th
Ave 53rd Street, New York, NY |
|
|
|
A live audio webcast of the investor meeting will
be available by visiting the investor relations section
of Endologix's website at www.endologix.com.
Participants are encouraged to log on a few minutes prior
to 5:00 pm ET in order to download any applicable audio
software. A replay of the presentation will be available within 24
hours and will be available for approximately one year.
Please RSVP by contacting Brandon Vazquez at The
Ruth Group at: bvazquez@theruthgroup.com or 646-536-7032
by November 14, 2016.
About Endologix, Inc.Endologix,
Inc. develops and manufactures minimally invasive treatments for
aortic disorders. The Company's focus is endovascular stent grafts
for the treatment of abdominal aortic aneurysms (AAA). AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once AAA develops, it
continues to enlarge and, if left untreated, becomes increasingly
susceptible to rupture. The overall patient mortality rate for
ruptured AAA is approximately 80%, making it a leading cause of
death in the U.S. Additional information can be found on
Endologix's website at www.endologix.com.
ENDOLOGIX CONTACT:
Endologix, Inc.
John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200
www.endologix.com
INVESTOR CONTACTS:
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024